• Medical_Professionals
• Medical_students
• Nurses

Dear Friends and Colleagues,

We would like to welcome you to the 3rd Science of Hepatitis B Cure Symposium to be held from 8 and 9 June 2018. Since the discovery of the “Australia Antigen” by Baruch Bloomberg in 1963 and then the hepatitis B virus (HBV) in 1970 by David Dane, much has been learned about the virus, but we are still some way from “curing” hepatitis B. The great successes of the direct acting antiviral agents (DAA) in curing hepatitis C has re-invigorated the hepatitis B field. New targets for drug development in hepatitis B has already resulted in over 20 different novel therapeutic agents entering clinical trials.  This is a very exciting time to be involved in hepatitis B and in this meeting, we have assembled expert researchers who are able to provide insights into strategies and mechanisms that may lead to a cure. Of course, this meeting also discusses what is meant by “cure” and how current and future therapies are likely to achieve this.

We will also update you on an exciting new initiative designed to coordinate global efforts to cure hepatitis B. The International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) is an international, independent and neutral initiative aiming at promoting awareness and education on HBV as well as driving changes in government policy to ensure that funds are channeled towards HBV cure research and drug development. ICE-HBV will be an evidence-based coalition of scientific working groups on HBV virology, immunology, innovative tools and clinical trials who work together with patients and other stakeholders to accelerate research towards an HBV cure. We will also be including an industry symposium to hear the latest agents for HBV and end with a forum on how to combine agents in combination to achieve a cure.

This meeting caters to clinicians, researchers, scientists and students who are interested in how a “cure” of HBV may be achieved. I would strongly encourage all those interested to attend and participate in this exciting meeting, with state of the art talks by prominent researchers in the field.

Sincerely,

Professor Seng Gee Lim

Chairman

Singapore Hepatitis Conference

Professor Stephen Locarnini

Divisional Head, Research & Molecular Development

Victorian Infectious Diseases Reference Laboratory

Director, WHO Regional Reference Laboratory for Hepatitis B

Doherty Institute (University of Melbourne)

Australia

Associate Professor Peter Revill

Research and Molecular Development

Victorian Infectious Diseases Reference Laboratory

President, Australasian Centre for Hepatitis Virology,

Executive member, Australian Center for HIV and Hepatitis Virology (ACH2)

Australia

Massimo Levrero

Professor Levrero is Professor of Medicine at the Sapienza University in Rome, Italy. He has recently joined the Centre de Recherche en Cancérologie de Lyon (CRCL) in Lyon, France, where he leads a Research Unit on ”Epigenetics and Epigenomics of Hepatocellular Carcinoma”, and the Service d’Hepatologie et Gastroenterologie - Hopital de la Croix Rousse - Hospices Civils de Lyon, France, where he continues his academic practice in hepatology. He serves as Associate Member and Director of the Functional Genomics platform at the IIT-Sapienza Center for Life NanoScience (CLNS) in Rome

Italy

Sharon Lewin 

Prof Lewin is the inaugural director of the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and Royal Melbourne Hospital; Professor of Medicine, The University of Melbourne; consultant infectious diseases physician, Alfred Hospital and a National Health and Medical Research Council (NHMRC) Practitioner Fellow. Her research focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. She is passionate about research translation, science communication and the role of community in research and health.

Australia

Lim Seng Gee

Prof Lim is Director of Hepatology, Dept of Gastroenterology & Hepatology National University Hospital, Chairman of the Singapore Hepatitis Conference, Governing Council Member, International Association for Study of Liver; and Adjunct Principal Investigator, Institute of Molecular and Cell Biology, ASTAR

Singapore

Stephen Locarnini 

Prof Locarnini is a Head of Department at Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, University of Melbourne, WHO Regional Reference Laboratory for Hepatitis B. His research interests include Hepatitis A, B, C, D, E, public health, co-infection with HIV, pathogenesis, cure strategies.

Australia

Veronica Miller

Dr Miller is the Executive Director of the Forum for Collaborative HIV Research (The Forum), a Senior Researcher and Lecturer at the UC Berkeley School of Public Health. A leading expert resolving significant health policy and public health issues, she has extensive experience working with major global and US organizations and agencies involved in HIV, HCV, HBV, CMV, PSC and fatty liver disease research and regulatory policy. 

USA

Peter Revill 

Professor Revill is a Senior Medical Scientist at the Victorian Infectious Diseases Reference Laboratory (VIDRL), Section Head of the Molecular Virology Group, Division of Research and Molecular Development and the President of Australasian Centre for Hepatitis Virology.

Australia

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Submission Info

The Science of HBV Cure Secretariat

c/o Singapore Hepatitis Conference Pte Ltd

20 Maxwell Road

#09-17 Maxwell House

Singapore 069113

Tel: +65 6408 9790

Email: info@shc-sg.com

The Science of HBV Cure Secretariat

c/o Singapore Hepatitis Conference Pte Ltd

20 Maxwell Road

#09-17 Maxwell House

Singapore 069113

Tel: +65 6408 9790

Email: info@shc-sg.com